Cargando…
Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease
BACKGROUND: Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease. METHODS: We present a series of four cases in which administration of ritux...
Autores principales: | León Román, Francisco, Pintado-Cort, Beatriz, García-Casado, Diana, Muñiz-González, Francisco, López García-Asenjo, José Antonio, Díaz-Rodríguez, Cristina, Montoro-López, María Nieves, Loucel-Bellino, Mauricio, Recio-Moreno, Beatriz, Rebollo-Garrido, Sara, Martínez-Hernández, Yaiza, Cusacovich, Ivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496654/ https://www.ncbi.nlm.nih.gov/pubmed/37673443 http://dx.doi.org/10.1136/rmdopen-2023-003479 |
Ejemplares similares
-
Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease
por: Nishina, Naoshi, et al.
Publicado: (2020) -
Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study
por: Abe, Kazuya, et al.
Publicado: (2023) -
Impact of patient ancestry on heterogeneity of Sjögren’s disease
por: Beydon, Maxime, et al.
Publicado: (2023) -
Autoantibody status according to multiparametric assay accurately estimates connective tissue disease classification and identifies clinically relevant disease clusters
por: Cafaro, Giacomo, et al.
Publicado: (2023) -
A prediction model for progressive disease in systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2015)